Abstract
The discovery and characterization of two new chemical classes of potent and selective Polo-like kinase 1 (PLK1) inhibitors is reported. For the most interesting compounds, we discuss the biological activities, crystal structures and preliminary pharmacokinetic parameters. The more advanced compounds inhibit PLK1 in the enzymatic assay at the nM level and exhibit good activity in cell proliferation on A2780 cells. Furthermore, these compounds showed high levels of selectivity on a panel of unrelated kinases, as well as against PLK2 and PLK3 isoforms. Additionally, the compounds show acceptable oral bioavailability in mice making these inhibitors suitable candidates for further in vivo activity studies.
Copyright © 2011 Elsevier Ltd. All rights reserved.
MeSH terms
-
Administration, Oral
-
Algorithms
-
Animals
-
Cell Cycle Proteins / antagonists & inhibitors*
-
Cell Line, Tumor
-
Cell Proliferation / drug effects
-
Chemistry, Pharmaceutical / methods
-
Dose-Response Relationship, Drug
-
Drug Design
-
Drug Screening Assays, Antitumor / methods
-
Enzymes / chemistry
-
Humans
-
Mice
-
Models, Chemical
-
Polo-Like Kinase 1
-
Protein Isoforms
-
Protein Serine-Threonine Kinases / antagonists & inhibitors*
-
Proto-Oncogene Proteins / antagonists & inhibitors*
-
Pyridones / chemistry*
-
Pyridones / pharmacology
-
Pyrimidines / chemical synthesis
-
Pyrimidines / pharmacology*
-
Pyrroles / chemical synthesis
-
Pyrroles / chemistry*
-
Pyrroles / pharmacology
-
Tumor Suppressor Proteins
Substances
-
1,5,6,7-Tetrahydro-4H-pyrrolo(3,2-c)pyridine-4-one
-
5-(2-amino-pyrimidin-4-yl)-1H-pyrrole
-
Cell Cycle Proteins
-
Enzymes
-
Protein Isoforms
-
Proto-Oncogene Proteins
-
Pyridones
-
Pyrimidines
-
Pyrroles
-
Tumor Suppressor Proteins
-
PLK3 protein, human
-
PLK2 protein, human
-
Protein Serine-Threonine Kinases